These observations are complemented by studies showing that NF-κB inhibition is a promising strategy for prostate cancer treatment, and, particularly, as a chemo- or radio-sensitisation strategy (Palayoor et al, 1999; Altuwaijri et al, 2003; Flynn et al, 2003; Kikuchi et al, 2003; Chendil et al, 2004). The gene discussed is NFKB1; the disease is Familial prostate cancer.